

Tirbanibulin for actinic keratosis

NHS Devon

Commissioning policy

The routine commissioning of tirbanibulin is accepted in Devon for the field treatment of mild to moderate (non-hyperkeratotic, non-hypertrophic) actinic keratosis of the face or scalp in adults. The Formulary Interface Group should include this in locally defined treatment recommendations.

Rationale for the decision

Tirbanibulin ointment (Klisyri®) is applied to the skin for the field treatment of mild to moderate actinic keratosis. The efficacy and safety profile of Tirbanibulin was reported in 2 identical randomised controlled trials comparing the active agent to vehicle (placebo) control. 57 days post commencement of treatment, the pooled complete clearance rate for those treated with tirbanibulin was 49% compared to 8% with control. The most common adverse event from tirbanibulin use was mild to moderate skin reactions, all of which were easily managed or spontaneously resolved. There are no data directly comparing the effectiveness of tirbanibulin with more established agents. Cost comparisons with the most used treatment for this indication in Devon (5-fluorouracil 5% cream), suggest that tirbanibulin is a more expensive treatment option. The management of patients with actinic keratosis often involves repeated courses of topical therapy. It is therefore considered that tirbanibulin offers an alternative treatment option for patients who suffer unacceptable side effects to 5-fluorouracil 5% cream.

Guidance notes on exceptionality

Not applicable.

Date of publication:	Version:
26.09.2022	Policy agreed by NHS Devon ICB